NDASUBLINGUALTABLET
Approved
Jul 2013
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
5/8 — Partial
ZUBSOLV (buprenorphine hydrochloride and naloxone hydrochloride) by Bridge Therapeutics is naloxone. First approved in 2013.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZUBSOLV is a sublingual tablet combining buprenorphine hydrochloride (a partial mu-opioid agonist and kappa-opioid antagonist) with naloxone hydrochloride (an opioid antagonist) for the treatment of opioid use disorder. The buprenorphine component provides maintenance therapy with lower abuse potential, while the naloxone component discourages intravenous misuse by precipitating withdrawal symptoms if injected. Approved in 2013, ZUBSOLV represents a formulation innovation in the opioid maintenance therapy landscape, competing within the established buprenorphine/naloxone segment.
$0.0BPart D
6.4 years to LOEMechanism of Action
naloxone. Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. Naloxone is an opioid antagonist and produces opioid withdrawal signs and symptoms in individuals physically dependent on full opioid agonists when administered parenterally.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population
Started Nov 2013
33 enrolled
Opioid Dependence
Career Relevance
ZUBSOLV employs brand management, medical science liaison, and field sales roles focused on opioid use disorder treatment advocacy and payer relationship management. Success in this role requires deep knowledge of addiction medicine, pain management, behavioral health integration, and familiarity with SAMHSA regulations and DEA scheduling compliance. Currently 0 linked job openings are documented, reflecting the mature, stable nature of the product with established field infrastructure.
Worked on ZUBSOLV at Bridge Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.